omniverse: safety and tolerability of oral azacitidine plus venetoclax in patients with aml
Published 1 year ago • 130 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:51
rationale of omniverse: oral azacitidine venetoclax in patients with r/r or newly diagnosed aml
-
3:50
investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
5:36
venetoclax and azacitidine in mds patients
-
2:37
maintenance venetoclax and 5-azacytidine in patients with aml
-
7:50
which aml patients benefit most from venetoclax treatment?
-
12:05
venetoclax combinations, safety and efficacy
-
4:58
building blocks of hope - treatment of higher risk mds
-
1:48
azacitidine and venetoclax maintenance post allosct in high-risk t-all
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
3:17
venetoclax with azacitidine in hr-mds
-
3:35
safety and efficacy of venetoclax-based regimens for aml
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
1:50
the challenge of treating elderly patients with aml with venetoclax plus azacitidine
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
5:31
the role of venetoclax in older patients with aml
-
2:57
acquired resistance mutations in patients with aml treated with hma plus venetoclax
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:08
the importance of predicting venetoclax response in patients with aml
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
2:30
real-world outcomes of venetoclax azacitidine versus intensive chemotherapy in newly diagnosed aml